Inspiration Healthcare Group Plc · LSE:IHC
Inspiration Healthcare — FY2018 Earnings Presentation
22 slides from Inspiration Healthcare's earnings presentation, April 2018
Slide 1: Inspiration Healthcare Group plc Investor Presentation
Inspiration Healthcare Group plc Investor Presentation Year Ended 31st January 2018 April 2018
Slide 2: Our Business
Our Business Our vision • To improve patient outcomes in critical care Our mission • To develop outcome-enhancing products for intensive care patients and to promote these globally. We are passionate about improving patient Hypothermia Station outcomes through innovation, research and life-saving cu
Slide 3: Financial year ending January 2018
Financial year ending January 2018 ACHIEVING GROWTH IN A YEAR OF INTERNAL RESTRUCTURE Achievements “We plan to maintain our returns on a growing revenue line” Investment in management/ regulatory resources Increase investment in R&D Capital Reduction complete 3 new products launched New R&D centre 2
Slide 4: Financial Headlines
Financial year ended January 2018 Financial Headlines • Revenue grew 8% to £15.5m – 9% excluding discontinued industrial revenue in 2017 – Growth in both International and Domestic revenue – Focus on existing product range – gross margin in line with prior year • Planned increased regulatory costs •
Slide 5: Consolidated Income Statement
Consolidated Income Statement Audited Audited FY 2018 FY 2017 £’000 £’000 Revenue 15,495 14,323 Gross Profit 6,784 6,358 Operating profit 1,204 1,163 Exceptional items - (718) Finance (Expense)/Income (2) (1) Profit/(Loss) before tax 1,202 444 Taxation 21 (132) Profit/(Loss) after tax 1,223 312 EBIT
Slide 6: Revenue by Product Ownership FY2018
Revenue by Product Ownership FY2018 Technical Support 12% (2017: 12%) Other 1% Inspiration Branded (2017: 2%) 45% (2017: 45%) Distributed 42% (2017: 41%) 5
Slide 7: Revenue by Market Sector FY2018
Revenue by Market Sector FY2018 Critical Care £11.1M Operating Theatre Thermoregulation £1.7M Respiratory Thermoregulation Brain Monitoring Medos Acutronic Acutronic Novalung Operating Theatre £1.7m(11%) 2017: £1.9m Critical Care £11.1m (72%) 2017: £10.0m Home Healthcare £2.7m (17%) 2017: £2.4m Home
Slide 8: Revenue by Geography FY2018
Revenue by Geography FY2018 Rest of World Middle East & 2% Africa 5% Americas 6% Europe 18% Domestic 69% 7
Slide 9: Consolidated Cash Flow
Consolidated Cash Flow Audited Audited FY 2018 FY 2017 Profit before taxation 1,202 444 Depreciation & Amortisation 230 204 Impairment of goodwill and intangible assets - - Movement in working capital (542) 120 Other 31 3 Net cash generated from operations 921 771 Taxation 34 (203) Purchase of tangi
Slide 10: Capex
Capex £800 FY2018 £700 £600 £500 £000’s £400 FY2017 FY2017 £300 FY2018 £200 £100 £0 Tangible Assets Intangible Assets 9
Slide 11: Consolidated Balance Sheet
Consolidated Balance Sheet • 40% increase in net assets Audited Audited FY 2018 FY 2017 £’000 £’000 Non-Current Assets 1,782 1,006 Cash 2,086 2,165 Other Current Assets 3,625 3,269 Total Liabilities (3,128) (3,315) Net Assets 4,365 3,125 10
Slide 12: Consistent Revenue Growth
Consistent Revenue Growth Revenue £15.49M £14.32M £13.10M £9.54M £8.84M £7.99M £6.86M £6.02M £5.35M £3.22M £2.77M £1.59M £0.63M £1.10M £1.20M 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Slide 13: Strategic Markets
Strategic Markets Critical Care and Operating Theatre Critical Care of the Newborn Operating Theatre • Approx. 15m births pa in target markets • 4.7m Surgical Admissions in UK in 2013/14 • 10% of all live births in developed world (up 27% on 10 years)** need resuscitation • 51m in patient surgical p
Slide 14: Strategic Markets Portfolio in NICU & the Operating Theatre
Strategic Markets Portfolio in NICU & the Operating Theatre Neonatal Operating Theatre • Respiratory • Patient Warming • Neurological • ENT* • Resuscitation • Perfusion* • Thermoregulation • Pain Management* • Other disposables* *Distribution Only 13
Slide 15: Consumable, Capital & Tech. Support
Consumable, Capital & Tech. Support Portfolio Creation • Create best in class product portfolio • Ensure add value • Create strong margins • Ensure drop through to Operating Profit • Acquire vs Develop vs Licence Neonatal Warming Patient Tech Support Warming & Emergency (surgery) Hire Neonatal Respi
Slide 16: New Products – Market Approval 2018
New Products – Market Approval 2018 LifeStart Inspire rPAPTM Driver Neonatal Resuscitation Gas control system for rPAP Platform that facilitates Generator that can deliver optimal cord clamping resuscitation breaths to the newborn Unique+ CFM Cerebral Function Monitoring for the newborn brain with e
Slide 17: Acquisition Targets
Acquisition Targets Neonatal Intensive Care -Thermo-regulation Operation Theatre - Respiratory Support - Thermo-regulation - Resuscitation Neonatal Intensive Care Operating Theatre - Jaundice Management - Anaesthesia - Positioning / Developmental - Monitoring - Neurological Neonatal Intensive Care O
Slide 18: Outlook
Outlook Outlook – short term Outlook – longer term Continuation of underlying organic Develop markets further over 3 years growth – esp. USA Gathering momentum during the year Continual investment from our balance sheet to grow business over the next 3 years New Product Releases as R&D Pipeline New
Slide 19: Appendices
Appendices
Slide 20: The Inspiration Story
The Inspiration Story Sales Sales Sales Sales Sales Sales Sales c.£0.6m c.£1.6m c.5.3m c.9.5m c.13.1m c.14.3m c.15.5m 2003 2007 2010 2015 2016 2017 2018 Distribution of Licensed Launched Listed on AIM Consolidated Outsource 3 new 4 products in Tecotherm Inspire nCPAP & Manufacturing products UK reen
Slide 21: Shareholder Base
Shareholder Base Institutional Shareholders 28% Management Shareholders 50% Notifiable Private Investors 10% Other/ Free Float 12% 20
Slide 22: Disclaimer
DISCLAIMER • While the information contained herein has been prepared by Inspiration Healthcare Group plc (“Inspiration”) in good faith, neither it nor any of its directors, officers, agents, advisers, affiliates or employees makes any representation or warranty, express or implied, nor shall any of
Inspiration Healthcare Group — FY2018 Earnings Presentation on 6ix